• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用贝沙罗汀和地尼白介素-妥昔单抗治疗的晚期原发性皮肤T细胞淋巴瘤

Advanced-stage primary cutaneous T-cell lymphoma treated with bexarotene and denileukin diftitox.

作者信息

Cervigón-González Iván, Torres-Iglesias Luis Miguel, Palomo-Arellano Angel, Gil-Pascual Braulio

机构信息

Dermatology and Anatomical Pathology Unit, Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain.

出版信息

Case Rep Dermatol. 2011 Jan;3(1):13-7. doi: 10.1159/000324185. Epub 2011 Feb 5.

DOI:10.1159/000324185
PMID:21931572
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3175357/
Abstract

Advanced-stage primary cutaneous T-cell lymphoma has an unfavorable prognosis and low survival rates. Aggressive treatment with chemotherapy is not curative and causes considerable side effects. The combination of bexarotene and denileukin diftitox is associated with an acceptable safety profile and a likely synergistic effect because bexarotene is capable of modulating expression of IL-2 receptor and enhance the susceptibility of T-cell leukemia cells to denileukin diftitox. In the case reported here, the response to this combined treatment was satisfactory and well tolerated. The patient showed a complete regression of pruritus, restlessness, and insomnia. Skin lesions improved partially, and lymphadenopathy was reduced and finally disappeared completely.

摘要

晚期原发性皮肤T细胞淋巴瘤预后不良，生存率低。积极的化疗不能治愈疾病，且会引起相当多的副作用。贝沙罗汀和地尼白介素联合使用具有可接受的安全性，且可能具有协同作用，因为贝沙罗汀能够调节白细胞介素-2受体的表达，并增强T细胞白血病细胞对地尼白介素的敏感性。在本文报道的病例中，联合治疗的反应令人满意，耐受性良好。患者的瘙痒、烦躁和失眠完全消退。皮肤病变部分改善，淋巴结病减轻，最终完全消失。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a48/3175357/6df798290e3f/cde0003-0013-f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a48/3175357/7ed6b5302188/cde0003-0013-f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a48/3175357/62f9d5789702/cde0003-0013-f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a48/3175357/6df798290e3f/cde0003-0013-f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a48/3175357/7ed6b5302188/cde0003-0013-f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a48/3175357/62f9d5789702/cde0003-0013-f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a48/3175357/6df798290e3f/cde0003-0013-f03.jpg

相似文献

1
Advanced-stage primary cutaneous T-cell lymphoma treated with bexarotene and denileukin diftitox.使用贝沙罗汀和地尼白介素-妥昔单抗治疗的晚期原发性皮肤T细胞淋巴瘤
Case Rep Dermatol. 2011 Jan;3(1):13-7. doi: 10.1159/000324185. Epub 2011 Feb 5.
2
A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.贝沙罗汀与地尼白介素-妥西莫单抗联合治疗复发或难治性皮肤T细胞淋巴瘤的1期试验。
Blood. 2005 Jul 15;106(2):454-7. doi: 10.1182/blood-2004-11-4570. Epub 2005 Apr 5.
3
Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case.外用白介素融合毒素（Ontak）和贝沙罗汀（Targretin）治疗鼻型结外自然杀伤/T细胞淋巴瘤的病例报告
Br J Dermatol. 2006 May;154(5):988-91. doi: 10.1111/j.1365-2133.2006.07151.x.
4
Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.贝沙罗汀与DAB(389)IL-2（地尼白介素-妥昔单抗，商品名ONTAK）治疗皮肤T细胞淋巴瘤：治疗方案
Clin Lymphoma. 2000 Nov;1 Suppl 1:S51-5. doi: 10.3816/clm.2000.s.010.
5
Treatment of cutaneous T cell lymphoma: current status and future directions.皮肤T细胞淋巴瘤的治疗：现状与未来方向
Am J Clin Dermatol. 2002;3(3):193-215. doi: 10.2165/00128071-200203030-00006.
6
CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.CD25表达与皮肤T细胞淋巴瘤的组织学分级及对地尼白介素妥昔单抗的反应相关。
J Invest Dermatol. 2006 Mar;126(3):575-83. doi: 10.1038/sj.jid.5700122.
7
Interventions for mycosis fungoides.蕈样肉芽肿的干预措施。
Cochrane Database Syst Rev. 2012 Sep 12(9):CD008946. doi: 10.1002/14651858.CD008946.pub2.
8
Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene.用地尼白介素-毒素融合蛋白和口服贝沙罗汀治疗蕈样肉芽肿。
Clin Lymphoma Myeloma. 2006 May;6(6):488-92. doi: 10.3816/CLM.2006.n.031.
9
Bexarotene in the treatment of cutaneous T-cell lymphoma.贝沙罗汀治疗皮肤T细胞淋巴瘤
Expert Opin Pharmacother. 2006 May;7(7):907-15. doi: 10.1517/14656566.7.7.907.
10
Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.用地尼白介素妥西罗汀治疗的皮肤T细胞淋巴瘤患者反应和生存的生物学关联。
Clin Lymphoma Myeloma. 2006 Nov;7(3):199-204. doi: 10.3816/CLM.2006.n.059.

引用本文的文献

1
Follow-up of patients with mycosis fungoides after interferon α2b treatment failure.α2b干扰素治疗失败后蕈样肉芽肿患者的随访
Postepy Dermatol Alergol. 2015 Apr;32(2):67-72. doi: 10.5114/pdia.2014.40941. Epub 2015 Mar 30.

本文引用的文献

1
Denileukin diftitox therapy for patients with tumour-stage mycosis fungoides.
Dermatol Clin. 2008 Jan;26 Suppl 1:21-2.
2
Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma.
Clin Lymphoma Myeloma. 2007 Sep;7(8):541-5. doi: 10.3816/clm.2007.n.040.
3
Denileukin diftitox as novel targeted therapy for lymphoid malignancies.地尼白介素-妥西毒素作为淋巴恶性肿瘤的新型靶向治疗药物。
Cancer Invest. 2007 Sep;25(6):495-501. doi: 10.1080/07357900701360096.
4
Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.用地尼白介素妥西罗汀治疗的皮肤T细胞淋巴瘤患者反应和生存的生物学关联。
Clin Lymphoma Myeloma. 2006 Nov;7(3):199-204. doi: 10.3816/CLM.2006.n.059.
5
Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case.外用白介素融合毒素（Ontak）和贝沙罗汀（Targretin）治疗鼻型结外自然杀伤/T细胞淋巴瘤的病例报告
Br J Dermatol. 2006 May;154(5):988-91. doi: 10.1111/j.1365-2133.2006.07151.x.
6
A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.贝沙罗汀与地尼白介素-妥西莫单抗联合治疗复发或难治性皮肤T细胞淋巴瘤的1期试验。
Blood. 2005 Jul 15;106(2):454-7. doi: 10.1182/blood-2004-11-4570. Epub 2005 Apr 5.
7
Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication.皮肤T细胞淋巴瘤中急性超敏反应事件与DAB(389)IL-2（地尼白介素-妥索妥，ONTAK）的生物学关联：类固醇预处理可降低其发生频率和严重程度。
Clin Lymphoma. 2001 Mar;1(4):298-302. doi: 10.3816/clm.2001.n.005.
8
Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.口服贝沙罗汀（他扎罗汀胶囊）治疗难治性或持续性早期皮肤T细胞淋巴瘤的2期和3期临床试验。
Arch Dermatol. 2001 May;137(5):581-93.
9
Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.贝沙罗汀治疗难治性晚期皮肤T细胞淋巴瘤有效且安全：多国II-III期试验结果
J Clin Oncol. 2001 May 1;19(9):2456-71. doi: 10.1200/JCO.2001.19.9.2456.
10
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.两种剂量水平的地尼白介素-妥西罗莫司治疗皮肤T细胞淋巴瘤的关键III期试验。
J Clin Oncol. 2001 Jan 15;19(2):376-88. doi: 10.1200/JCO.2001.19.2.376.